吉西他滨联合奥沙利铂治疗晚期非小细胞肺癌

Gemcitabine and Oxaliplatin Combination Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

目的:观察吉西他滨(GEM)联合奥沙利铂(LOHP)治疗晚期非小细胞肺癌的临床疗效及不良反应。方法:35例Ⅲb期,IV期,经病理学或者细胞学确诊为非小细胞肺癌患者,采用GEM与LOHP联合化疗,GEM1250mg/m2,静脉滴注,第1天、8天,LOHP 130mg/m2静脉滴注,第1天,21天为1周期,连用2周期后评价疗效及不良反应。结果:全组CR 2例,PR 15例,有效率48.57%,主要不良反应为白细胞及血小板减少,外周神经炎。结论:GEM联合LOHP治疗晚期非小细胞癌疗效好,不良反应轻。

Objective： To evaluate the efficacy and toxicity of gemcitabine （GEM） and oxaliplatin （LOHP） combination chemotherapy in patients with advanced non - small - cell lung cancer. Methods： 35 patients with advanced NSCLC diagnosed path- ologically were treated with the combination chemotherapy （ GEM 1250 mg/m^2 on day 1.8 and LOHP130 mg/m^2 on day 1 ）. Each pa- tient was given 2 cycles at an interval of 3 weeks, and the efficacy and toxicity were then evaluated. Results： The overall response rate was 48.57%. The main toxicity was thrombocytopenia, leucocytopenia and peripheral nervous toxicity. Conclusion： The combi- nation chemotherapy of gemcitabine and oxaliplatin is an effective chemotherapy with acceptable toxicities for advanced NSCLC.